SAMI Pharmaceuticals Pvt. Ltd.
Manufacturer Holds a DRAP Drug Manufacturing Licence (DML) for its products. Source: DRAP.
Follow price changes 🔒 Company report (Pharma Pro)Private pharmaceutical manufacturer · Karachi · Pakistan
Karachi-based pharmaceutical manufacturer and marketer of branded generic medicines across major therapeutic categories.
What is sourced, and how recent is it?
Regulatory-source portfolio data and company-supplied/corporate profile fields are tracked separately. Company claim/verification status is separate from source quality. An unclaimed company can still have a fully official-source-observed portfolio.
Company profile
- Legal / official name
- SAMI Pharmaceuticals (Pvt.) Ltd.
- Company type
- Private pharmaceutical manufacturer
- Address
- 34-C, Block-6, P.E.C.H.S., Karachi-75350, Pakistan · 75350
- Website
- samipharma.com ↗
- Phone
- +92 21 34527490-92
- samiho@samikhi.com
- Official contact
- Contact page ↗
- Corporate source details checked
- 16 Aug 2026
- Corporate profile completeness
- 100%
Company location
A sourced company location is recorded. Use the map link below for directions.
Portfolio at a glance
RegistrationA unique regulatory registration number. One registration may have more than one strength/form/pack presentation.
PresentationA distinct medicine presentation, such as a particular strength, dosage form and pack.
IndexedA canonical MedInfoBase presentation that passed MedInfoBase identity and publication controls.
Source observedAn additional presentation observed in an official DRAP source but not counted as an indexed MedInfoBase presentation.
Registry onlyAn exact registry-verified registration not otherwise represented by an indexed or source-observed presentation.
Registry verifiedAn exact registration match found in an official DRAP registry source. This is evidence status, not a commercial ranking.
How complete is this profile?
Downloadable company intelligence charts
Copy or download any chart as a presentation-ready PNG. Every exported chart keeps MedInfoBase attribution and the source company-profile URL.
Therapeutic Portfolio Mix
Shows where the company portfolio is concentrated across broad therapeutic areas.
Portfolio distribution, not sales or market-share data.
Dosage Form Portfolio
Shows how the company portfolio is distributed across tablets, capsules, injections, liquids and other forms.
Counts are product presentations, not production or sales volumes.
Equivalent Price Position
Shows whether safely comparable products are below, near or above the peer median unit price.
This is price-position intelligence, not sales, demand or market-share data.
Closest Portfolio Competitors
Highlights other manufacturers with the greatest generic overlap with this company portfolio.
Competitor ranking is based on shared generics in MedInfoBase, not commercial sales performance.
Therapeutic areas
High-level clinical areas represented by this company’s current MedInfoBase portfolio.
Drug classes
More specific classes derived from the canonical generic and preserved curated classifications.
Dosage forms
How MedInfoBase classifies the portfolio
MedInfoBase uses a two-level taxonomy. Therapeutic area is a broad portfolio category, while drug class is the more specific pharmacological or clinical class. Existing curated classifications are preserved. Blank records are assigned conservatively from the canonical generic name and, when available, ATC information. Multi-use medicines may be placed in a cross-therapeutic category rather than forced into a single indication.
Deepest brand families
Unit-price positioning vs equivalent products
See where SAMI Pharmaceuticals Pvt. Ltd. is priced against the market
179 of its products have like-for-like competitors. Pharma Pro shows how many are priced below, near or above the market median, the company's overall price position, and product-by-product examples.
How MedInfoBase calculates price position
Only current prices with safely interpretable pack quantities are used. A product is compared only with the same generic, same stated strength, same dosage form and a compatible unit basis such as tablet, capsule, mL or gram. These are database-derived price comparisons, not sales or market-share estimates.
Portfolio overlap
Companies sharing the largest number of generics with this portfolio. This measures product overlap, not commercial performance.
🔒 3 more overlapping companies, with shared-generic detail, in Pharma Pro. Unlock
Observed database signals
These dates describe records observed by MedInfoBase. They should not be interpreted as product launch dates or sales activity.
Medicine portfolio
This unified portfolio keeps three evidence lanes distinct: indexed MedInfoBase presentations, additional source-observed presentations, and registry-only registrations that are not otherwise represented. A registration number is not the same thing as a presentation, and source-observed rows are not counted as indexed. Source-only rows with a strength/form/pack contradiction remain visible as evidence but the conflicting field is held for normalization.
| Brand | Generic | Strength | Form | Pack | Registration | Source-listed price | Unit price | Price position |
|---|---|---|---|---|---|---|---|---|
| RYBIO | Ribavirin | 500 mg | Tablet | 50's | 084737 | PKR 936.67 | PKR 18.73/tablet | 🔒 Pharma Pro |
| RYBIO | Ribavirin | 500 mg | Tablet | 10's | 084737 | PKR 203.62 | PKR 20.36/tablet | 🔒 Pharma Pro |
| RYBIO | Ribavirin | 500 mg | Tablet | 100's | 084737 | PKR 1,873.35 | PKR 18.73/tablet | 🔒 Pharma Pro |
| RYBIO | Ribavirin | 500 mg | Tablet | 20's | 084737 | PKR 386.87 | PKR 19.34/tablet | 🔒 Pharma Pro |
| RYBIO | Ribavirin | 500 mg | Tablet | 30's | 084737 | PKR 561.99 | PKR 18.73/tablet | 🔒 Pharma Pro |
| RYBIO | Ribavirin | 400 mg | Tablet | 30's | 086043 | PKR 507.02 | PKR 16.90/tablet | 🔒 Pharma Pro |
| RYBIO | Ribavirin | 400 mg | Tablet | 10's | 086043 | PKR 183.26 | PKR 18.33/tablet | 🔒 Pharma Pro |
| RYBIO | Ribavirin | 400 mg | Tablet | 20's | 086043 | PKR 348.20 | PKR 17.41/tablet | 🔒 Pharma Pro |
| SALTIV | Oseltamivir | 75 mg | Capsule | 10's | 101306 | PKR 1,549.00 | PKR 154.90/capsule | 🔒 Pharma Pro |
| SAMCLOM | Clomifene citrate | 50 mg | Tablet | 10's | 094925 | PKR 446.14 | PKR 44.61/tablet | 🔒 Pharma Pro |
| SAMOCHIN | Chloroquine | 250 mg | Tablet | 500's | 101304 | PKR 1,032.15 | PKR 2.06/tablet | 🔒 Pharma Pro |
| SAMULIN 70/30Source observed | Human insulin premix 30/70 (30% regular + 70% NPH) | 100 IU/mL | Injection | 1's Vial (10ml) | 120490Official source ↗ | No indexed price | — | — |
| SAMULIN 70/30Source observed | Human insulin (isophane/NPH) | 100 IU | Injection | 1's Vial (10ml) | 120490Official source ↗ | No indexed price | — | — |
| SAMULIN R | Regular human insulin | 100 IU/mL | Injection | 1's Vial (10ml) | 120489 | PKR 1,094.62 | — | No comparator |
| SAMULIN R | Human insulin (isophane/NPH) | 100 IU | Injection | 1's Vial (10ml) | 120489 | PKR 1,094.62 | — | No comparator |
| SAMULIN-NPH | Human insulin (isophane/NPH) | 100 IU/mL | Suspension for injection | 1's Vial (10ml) | 120491 | PKR 1,094.62 | — | No comparator |
| SAMULIN-NPH | Human insulin (isophane/NPH) | 100 IU | Injection | 1's Vial (10ml) | 120491 | PKR 1,094.62 | — | No comparator |
| Silesto 100mg TabletRegistry verified | Sildenafil Citrate Eq. to Sildenafil | — | — | — | 135047Official source ↗ | No indexed price | — | — |
| Silesto 25mg TabletRegistry verified | Sildenafil Citrate Eq. to Sildenafil | — | — | — | 135046Official source ↗ | No indexed price | — | — |
| Tadaflo 10mg TabletRegistry verified | Tadalafil | — | — | — | 135116Official source ↗ | No indexed price | — | — |
| Tadaflo 2.5mg TabletRegistry verified | Tadalafil | — | — | — | 135115Official source ↗ | No indexed price | — | — |
| Tadaflo 20mg TabletRegistry verified | Tadalafil | — | — | — | 134979Official source ↗ | No indexed price | — | — |
| Tadaflo 5mg TabletRegistry verified | Tadalafil | — | — | — | 135117Official source ↗ | No indexed price | — | — |
| TELARB-H | Telmisartan + Hydrochlorothiazide | 40 mg + 12.5 mg | Tablet | 28's | 100513 | PKR 1,216.47 | PKR 43.45/tablet | 🔒 Pharma Pro |
| TELARB-H | Telmisartan + Hydrochlorothiazide | 40 mg + 12.5 mg | Tablet | 14's | 100513 | PKR 640.22 | PKR 45.73/tablet | 🔒 Pharma Pro |
| TELARB-H | Telmisartan + Hydrochlorothiazide | 80 mg + 12.5 mg | Tablet | 28's | 100514 | PKR 2,292.50 | PKR 81.88/tablet | 🔒 Pharma Pro |
| TELARB-H | Telmisartan + Hydrochlorothiazide | 80 mg + 12.5 mg | Tablet | 14's | 100514 | PKR 1,208.22 | PKR 86.30/tablet | 🔒 Pharma Pro |
| TELARB-Plus | Telmisartan + Amlodipine | 40 mg + 5 mg | Tablet | 14's | 100515 | PKR 712.53 | PKR 50.90/tablet | 🔒 Pharma Pro |
| TELARB-Plus | Telmisartan + Amlodipine | 80 mg + 5 mg | Tablet | 30's | 100924 | PKR 2,042.59 | PKR 68.09/tablet | 🔒 Pharma Pro |
| TELARB-Plus | Telmisartan + Amlodipine | 80 mg + 5 mg | Tablet | 10's | 100924 | PKR 681.54 | PKR 68.15/tablet | 🔒 Pharma Pro |
| TELARB-Plus | Telmisartan + Amlodipine | 80 mg + 5 mg | Tablet | 14's | 100924 | PKR 954.16 | PKR 68.15/tablet | 🔒 Pharma Pro |
| TELARB-Plus | Telmisartan + Amlodipine | 80 mg + 5 mg | Tablet | 20's | 100924 | PKR 1,363.08 | PKR 68.15/tablet | 🔒 Pharma Pro |
| TELARB-Plus | Telmisartan + Amlodipine | 40 mg + 10 mg | Tablet | 30's | 100925 | PKR 1,544.84 | PKR 51.49/tablet | 🔒 Pharma Pro |
| TELARB-Plus | Telmisartan + Amlodipine | 40 mg + 10 mg | Tablet | 10's | 100925 | PKR 559.68 | PKR 55.97/tablet | 🔒 Pharma Pro |
| TELARB-Plus | Telmisartan + Amlodipine | 40 mg + 10 mg | Tablet | 14's | 100925 | PKR 805.54 | PKR 57.54/tablet | 🔒 Pharma Pro |
| TELARB-Plus | Telmisartan + Amlodipine | 40 mg + 10 mg | Tablet | 20's | 100925 | PKR 1,063.62 | PKR 53.18/tablet | 🔒 Pharma Pro |
| TELARB-Plus | Telmisartan + Amlodipine | 80 mg + 10 mg | Tablet | 14's | 100926 | PKR 1,187.54 | PKR 84.82/tablet | 🔒 Pharma Pro |
| TELARB-Plus | Telmisartan + Amlodipine | 80 mg + 10 mg | Tablet | 10's | 100926 | PKR 846.76 | PKR 84.68/tablet | 🔒 Pharma Pro |
| TePH | Omeprazole | 20 mg | Capsule | 14's | 018091 | PKR 878.98 | PKR 62.78/capsule | 🔒 Pharma Pro |
| TePH | Omeprazole | 40 mg | Capsule | 14's | 025595 | PKR 516.35 | PKR 36.88/capsule | 🔒 Pharma Pro |
| TePH | Omeprazole | 40 mg | IV infusion | Vial | 057830 | PKR 619.59 | PKR 619.59/vial/unit | 🔒 Pharma Pro |
| TIMEQUIN | Dihydroartemisinin + Piperaquine | 40 mg + 320 mg | Capsule | 8's | 070786 | PKR 821.63 | PKR 102.70/capsule | 🔒 Pharma Pro |
| TULAC | Lactulose | 66.70 g/100 mL | Syrup | 120ml | 045399 | PKR 293.24 | PKR 2.44/mL | No comparator |
| UBROF | Ibuprofen | 400 mg/100 mL | IV infusion | 100ml Vial | 097180 | PKR 427.11 | PKR 4.27/mL | 🔒 Pharma Pro |
| UBROF | Ibuprofen | 800 mg/8 mL | Injection | 8ml x 10's | 105262 | PKR 2,909.82 | PKR 36.37/mL | 🔒 Pharma Pro |
| UBROF | Ibuprofen | 800 mg/8 mL | Injection | 8ml x 1's | 105262 | PKR 303.13 | PKR 37.89/mL | 🔒 Pharma Pro |
| UBROF | Ibuprofen | 600 mg/100 mL | IV infusion | 100ml | 105263 | PKR 271.63 | PKR 2.72/mL | 🔒 Pharma Pro |
| VORY | Voriconazole | 200 mg | Tablet | 10's | 088209 | PKR 2,265.80 | PKR 226.58/tablet | 🔒 Pharma Pro |
| VORY | Voriconazole | 200 mg/5 mL | Suspension | 75ml | 088210 | PKR 3,223.63 | PKR 42.98/mL | 🔒 Pharma Pro |
| VORY | Voriconazole | 50 mg | Tablet | 10's | 088211 | PKR 823.94 | PKR 82.39/tablet | 🔒 Pharma Pro |
MedInfoBase company-intelligence methodology
This page is generated from MedInfoBase medicine, generic, company, price and official-source records. Unverified third-party discovery records are retained internally for coverage auditing and are not published as company registrations. Portfolio leaders are ranked by presentation depth, not sales. Price-position metrics are calculated from current official-source prices normalized to compatible units and compared only against like-for-like products with the same generic, stated strength and dosage form.
Not currently included: sales volume, revenue by brand, market share, prescription volume or best-selling rankings. MedInfoBase will display those only when supported by a defensible licensed, public or company-verified source.
Cite this record
Manufacturer recordRecords change over time. Please cite the access date so readers can locate the version you used.